
News|Articles|September 1, 2003
Treatment for male pattern baldness delays prostate cancer
Finasteride (Propecia, Merck), an inhibitor of 5a-reductase, prevents or delays the appearance of prostate cancer by 24.8% (P<.001), according to researchers from the University of Texas Health Science Center, San Antonio, Texas.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
2
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
3
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2025
4
Healthcare’s workforce has a scale problem, but new model is emerging
5


























